WO1997042946A1 - Alpha-bloquants (par exemple le moxisylyte et/ou ses derives) pour le traitement des dysfonctionnements erectils - Google Patents
Alpha-bloquants (par exemple le moxisylyte et/ou ses derives) pour le traitement des dysfonctionnements erectils Download PDFInfo
- Publication number
- WO1997042946A1 WO1997042946A1 PCT/FR1997/000837 FR9700837W WO9742946A1 WO 1997042946 A1 WO1997042946 A1 WO 1997042946A1 FR 9700837 W FR9700837 W FR 9700837W WO 9742946 A1 WO9742946 A1 WO 9742946A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- moxisylyte
- compound
- use according
- dam
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/41—Devices for promoting penis erection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
Definitions
- ALPHA-BLOCKERS FOR EXAMPLE MOXISYLYTE AND / OR ITS DERIVATIVES FOR THE TREATMENT OF ERECTTLS DYSFUNCTIONS
- the present invention relates to the use of compounds acting for the treatment of erectile dysfunctions, in particular of? compounds of the “alpha-blocker” type, for the formulation of various galenical compositions allowing treatment by the
- the invention relates more particularly to the use of Moxisylyte and / or its derivatives, in particular deacethyl-moxisylyte (DAM) or monodemethyl-deacethyl-moxisylyte (MDAM) as active ingredient of such compositions.
- DAM deacethyl-moxisylyte
- MDAM monodemethyl-deacethyl-moxisylyte
- Erectile dysfunctions are frequently encountered, their prevalence being around 4 to 9% in the general male population
- the erection does not only result from an arterial vasodilation followed by a filling of the cavernous bodies, but also and above all from a relaxation of the smooth muscle fibers of the cavernous areoles allowing the aspiration of blood inside the corpora cavernosa and venous compression by crushing the emissary veins against the albuginea
- Acetylcholine mediator of the parasympathetic system, controls the relaxation of smooth muscle fiber, more it seems by inducing the release of nitric oxide and vasoactive intestinal peptides (VIP) as well as P substances and CGRP (Calcitonin-gene-related-peptide) by the non-adrenergic-non-cholmergic endings and by the endothelium of the corpora cavernosa, only by a direct action on this fiber.
- VIP vasoactive intestinal peptides
- CGRP Calcitonin-gene-related-peptide
- PGE1 probably synthesized in the penis by the vascular endothelium, it could, in addition to its direct relaxing action on smooth muscle cells, also modulate the anti-erectile adrenergic tone by reducing the release of noradrenahne.
- alpha-adrenergic receptors is ten times higher than that of beta receptors, with a predominance of alpha-1 More recently, alpha-1 adrenergic receptors have been subdivided into three subtypes alpha-1 -ad, alpha-1 -b, and alpha-1 -c which are probably involved to varying degrees in mediating the contraction of smooth muscle cells and the human cavernous body
- this mode of administration remains disturbing for w approximately 50% of the patients, some of them going so far as to prefer intracavernous injection.
- this mode of administration also remains unpleasant for the partner, by the fact that it causes in her an intravaginal administration which is not necessary for her, as well as possible side effects
- the present invention proposes to solve the problems described above thanks to a non-invasive treatment and a great comfort of administration, using the properties of compounds acting for the treatment of erectile dysfunctions, in particular alpha-blockers such as moxisylyte and / or its derivatives
- the invention therefore relates to the use of such compounds, in particular
- DAM deacethyl moxisylyte
- I - ⁇ thymoxyéthymdiméthylamme is an alpha-blocker corresponding to the crude formula C ⁇ 6 H 25 N0 3 HCI
- moxisylyte is never found in the body as such. It is, in fact, immediately hydrolyzed by
- the DAM and the MDAM have, with regard to the contracting effects of noradrenahne, an activity of competitive type This activity is equivalent to that of the moxisylyte with regard to the DAM and slightly lower with regard to the MDAM
- sulpho-conjugated derivatives have an alpha-blocking activity but of less intensity
- the balanic mucosa indeed represents a histological continuity of the spongy body.
- the active principle can propagate to the spongy tissue so as to cause the intumescence of the latter, and thus allow the erectile process by the mechanism previously describes
- moxisylyte and its derivatives in particular DAM, are alone capable of penetrating the mucous membranes relatively easily and can therefore be used without being combined with agents for permeabilization or penetration of the balanic mucosa Nevertheless , the moxisylyte and / or its derivatives are preferably used in combination with one or more pharmacologically acceptable excipients, capable of dissolving the moxisylyte andyou said derivatives and / or of facilitating their transmucosal passage
- excipients capable of dissolving the compounds used according to the present invention are preferably selected from the groups comprising
- fatty esters such as isopropyl myristate, sodium methyl parahydroxybenzoate, dioctyl adipate, or dnsopropyl adipate
- benzyl cetyl alcohol such as benzyl cetyl alcohol, Myghol® 81 2 Labrafac®, Lab ⁇ fil®, Transcutol®, polyethylene glycol
- the excipients capable of facilitating the transmucosal passage of the moxisylyte derivatives are preferably selected from the group comprising N-methyl-pyrrohdone, pyrrolidone, N- N-dimethyltoluamide
- the moxisylyte derivative (s) are present in an amount of 1 to 20%, preferably 5 to 10% by weight relative to said excipients
- the medicament is in the form of a cream, lotion, plaster or gel ⁇ o
- the invention also relates to a device intended to cover at least the balanic mucosa of the penis, this device being coated in its part coming into contact with said mucosa of the medicament according to the use described above
- this device is a condom
- Such a means has the advantage of allowing the medicament
- DAM moxisylyte hydrochloride
- the DAM was dissolved in a mixture of ethanol and Mygliol® 50/50 or 3/97 (vol / vol) A known quantity of active ingredients
- DAM can be administered by
- a device which is more particularly suitable for use according to the present invention is the condom.
- This is coated internally with compositions comprising the compounds used for the treatment of erectile dysfunctions, such as moxisylyte and / or one of its derivatives, in particular galenical formulations above These are preferably associated with products or fatty substances having II
- Transcutol® Gattefosse 13 00 g hydroxypropyl methylcellulose 0 30 g sodium methyl parahydroxybenzoate 0 05 g
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97924075A EP0906093A1 (fr) | 1996-05-15 | 1997-05-13 | Alpha-bloquants (par exemple le moxisylyte et/ou ses derives) pour le traitement des dysfonctionnements erectils |
AU29662/97A AU2966297A (en) | 1996-05-15 | 1997-05-13 | Alpha blockers (e.g. moxisylyte and/or derivatives thereof) for treating erectile dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9606105A FR2748658B1 (fr) | 1996-05-15 | 1996-05-15 | Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique |
FR96/06105 | 1996-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997042946A1 true WO1997042946A1 (fr) | 1997-11-20 |
Family
ID=9492189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1997/000837 WO1997042946A1 (fr) | 1996-05-15 | 1997-05-13 | Alpha-bloquants (par exemple le moxisylyte et/ou ses derives) pour le traitement des dysfonctionnements erectils |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0906093A1 (fr) |
CN (1) | CN1225581A (fr) |
AU (1) | AU2966297A (fr) |
FR (1) | FR2748658B1 (fr) |
TR (1) | TR199802324T2 (fr) |
WO (1) | WO1997042946A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
WO2018073821A1 (fr) * | 2016-10-18 | 2018-04-26 | Vasolead (2012) Ltd. | Compositions et méthodes de traitement de la dysérection |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087240B1 (en) | 1998-06-25 | 2006-08-08 | Lavipharm Laboratories Inc. | Device and method for the treatment of erectile dysfunction |
IL140475A0 (en) * | 1998-06-25 | 2002-02-10 | Lavipharm Lab Inc | A device and method for the treatment of erectile dysfunction |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
FR2666507A1 (fr) * | 1990-09-07 | 1992-03-13 | Sarget Lab | Compositions pharmaceutiques pour l'administration topique de moxisylyte et de desacetyl moxisylyte et leurs utilisations en therapeutique. |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
WO1994004120A2 (fr) * | 1992-08-21 | 1994-03-03 | Roberto Dias Nahoum Cesar | Methode de traitement de defaillances sexuelles chez l'animal et chez l'homme au moyen d'un agonsite de h |
WO1995005172A1 (fr) * | 1993-08-13 | 1995-02-23 | Zonagen, Inc. | Methode de modulation de la reponse sexuelle chez l'homme |
WO1996032141A1 (fr) * | 1995-04-12 | 1996-10-17 | Sam Yang Co., Ltd. | Dispositif d'administration transdermique de medicament destine au traitement de dyserections |
-
1996
- 1996-05-15 FR FR9606105A patent/FR2748658B1/fr not_active Expired - Fee Related
-
1997
- 1997-05-13 TR TR1998/02324T patent/TR199802324T2/xx unknown
- 1997-05-13 EP EP97924075A patent/EP0906093A1/fr not_active Withdrawn
- 1997-05-13 CN CN 97196485 patent/CN1225581A/zh active Pending
- 1997-05-13 AU AU29662/97A patent/AU2966297A/en not_active Abandoned
- 1997-05-13 WO PCT/FR1997/000837 patent/WO1997042946A1/fr not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
FR2666507A1 (fr) * | 1990-09-07 | 1992-03-13 | Sarget Lab | Compositions pharmaceutiques pour l'administration topique de moxisylyte et de desacetyl moxisylyte et leurs utilisations en therapeutique. |
WO1994004120A2 (fr) * | 1992-08-21 | 1994-03-03 | Roberto Dias Nahoum Cesar | Methode de traitement de defaillances sexuelles chez l'animal et chez l'homme au moyen d'un agonsite de h |
WO1995005172A1 (fr) * | 1993-08-13 | 1995-02-23 | Zonagen, Inc. | Methode de modulation de la reponse sexuelle chez l'homme |
WO1996032141A1 (fr) * | 1995-04-12 | 1996-10-17 | Sam Yang Co., Ltd. | Dispositif d'administration transdermique de medicament destine au traitement de dyserections |
Non-Patent Citations (2)
Title |
---|
MONTORSI: "Pharmacological management of erectile dysfunction", DRUGS, vol. 50, no. 3, 1995, pages 465 - 479, XP002040420 * |
NEAU ET AL.: "Comparison of thymoxamine permeation between hairless rat and horse penile mucous membrane using an in-vitro diffusion model", SKIN PHARMACOL., vol. 7, no. 3, 1994, pages 121-121 - 129, XP002040421 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
WO2018073821A1 (fr) * | 2016-10-18 | 2018-04-26 | Vasolead (2012) Ltd. | Compositions et méthodes de traitement de la dysérection |
Also Published As
Publication number | Publication date |
---|---|
TR199802324T2 (xx) | 2001-01-22 |
FR2748658B1 (fr) | 2000-08-18 |
CN1225581A (zh) | 1999-08-11 |
EP0906093A1 (fr) | 1999-04-07 |
FR2748658A1 (fr) | 1997-11-21 |
AU2966297A (en) | 1997-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU710111B2 (en) | Methods and formulations for modulating the human sexual response | |
SK117597A3 (en) | Water-based topical cream containing nitroglycerin; method of preparation and use thereof | |
US6589990B1 (en) | Methods and compositions for misoprostol compound treatment of erectile dysfunction | |
KR100322042B1 (ko) | 비쇼그렌증후군성구강건조증치료제 | |
FR2765483A1 (fr) | Medicament destine a traiter les dysfonctions erectiles | |
WO1997042946A1 (fr) | Alpha-bloquants (par exemple le moxisylyte et/ou ses derives) pour le traitement des dysfonctionnements erectils | |
KR101072175B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 배뇨장애 치료제 및 부종 치료제조성물 | |
WO2011130608A1 (fr) | Procédés et compositions pour stimuler l'excitation sexuelle chez la femme et traiter un trouble sexuel chez la femme | |
WO2001049322A1 (fr) | Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un agent anti-hypertenseur pour une utilisation therapeutique dans le traitement de l'hypertension arterielle | |
Dinsmore | Available and future treatments for erectile dysfunction | |
US9265721B2 (en) | Composition for promoting vascular smooth muscle relaxation | |
BE1009851A3 (fr) | Composition pharmaceutique pour le traitement des cephalees et son utilisation. | |
Porst et al. | Self-injection, transurethral and topical therapy in erectile dysfunction | |
FR2519252A1 (fr) | Medicament a base de dihydrotestosterone pour le traitement des deficits des secretions androgeniques testiculaires | |
Burns-Cox et al. | Medical treatment of erectile dysfunction | |
BE857762A (fr) | Compositions pharmaceutiques pour le traitement des maladies vasculaires | |
BE1004015A3 (fr) | Formules pharmaceutiques pour le traitement des maladies vasculaires peripheriques. | |
WO2010044094A2 (fr) | Composition topique pour traiter un dysfonctionnement érectile | |
Jara et al. | Intracavernous methoxamine in the treatment of priapism | |
Hairston et al. | Topical and intraurethral therapy | |
KR20030030978A (ko) | 성기능 장애 치료용 생약 조성물 및 그 제조방법 | |
BE856642A (fr) | Solution aqueuse anti-inflammatoire et/ou analgesique et methode d'utilisation de cette solution | |
WO1999056728A1 (fr) | Prostaglandine pge-1 contenant des liposomes lyophilises utilisee pour le traitement d'une dysfonction erectile | |
CH682454A5 (fr) | Formules pharmaceutiques pour le traitement des maladies vasculaires périphériques. | |
Beauchesne | Male erectile dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97196485.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) |
Free format text: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO PATENT (GH, KE, LS, MW, SD, SZ, UG), EURASIAN PATENT (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), EUROPEAN PATENT (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI PATENT (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG) |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997924075 Country of ref document: EP Ref document number: 1998/02324 Country of ref document: TR |
|
NENP | Non-entry into the national phase |
Ref document number: 97540592 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997924075 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997924075 Country of ref document: EP |